Higher Risk Due to Health Conditions

COVID-19 Vaccination among People Living with HIV: Immunogenicity, Effectiveness, and Safety

Aslam Anis, University of British Columbia

COVID-19 may pose a greater risk to people living with HIV. This study is following 400 people living with HIV in Montreal, Ottawa, Toronto, and Vancouver to determine their COVID-19 immune responses. Researchers are also doing a population-based analysis of provincial public health to look at vaccine effectiveness in people living with HIV.
Research summary

Safety immUnogenicity of Covid-19 vaCcines in systEmic immunE mediated inflammatory Diseases (SUCCEED)

Sasha Bernatsky, Research Institute of the McGill University Health Centre (RI-MUHC)

This study is following more than 2,000 patients with various autoimmune inflammatory diseases (IMIDs) to determine their immune response to the COVID-19 vaccine. Researchers will provide patient groups, healthcare providers, and policy makers important information on immune response, safety and disease activity following vaccination in people living with IMIDs.
Research summary

A prospective multi-site observational study of SARS-CoV-2 vaccination immunogenicity in patients with hematologic malignancies

C. Arianne Buchan, Ottawa Hospital Research Institute

Individuals with blood cancers such as lymphoma, myeloma, and leukemia have weakened immune systems because of their disease and the treatments they receive. This Canada-wide study is looking at COVID-19 vaccine response and safety in people with blood cancers including those who have received stem cell transplants.
Research summary

Immune response after COVID-19 vaccination during maintenance therapy in immune-mediated inflammatory diseases: an observational cohort study (IMPACT)

Vinod Chandran, University Health Network

Currently, the efficacy of COVID-19 vaccines in patients with immune-mediated inflammatory diseases (IMID) is not known as they were excluded from the clinical trials. This study aims to determine whether IMID patients treated with immunosuppressive medications still generate a protective immune response to the original SARS-CoV-2 and new variants after COVID-19 vaccination.
Research summary

COVID-19 Vaccine Immunogenicity and Safety in Immunodeficient patients

Juthaporn Cowan, Ottawa Hospital Research Institute

People with low immune systems were not included in the clinical trials for COVID-19 vaccines so it’s not known how they respond to the vaccines. Researchers in six provinces are following participants who have inborn error of immunity or certain medication-induced immunodeficiency to evaluate their immune response to COVID vaccines and assess vaccine safety.
Research summary

Prospective Evaluation of COVID-19 Vaccine in Transplant Recipients (PREVenT-COVID): A National Strategy

Deepali Kumar, University Health Network

This study is following 600 transplant recipients from several high-volume transplant centres in Canada over one year to test the safety and effectiveness of COVID-19 vaccines in this immunosuppressed population. To assess long-term safety, researchers are developing a national safety surveillance system of COVID-19 vaccination amongst transplant recipients through the CANVAS network.
Research summary Results

Determining the safety and effectiveness of COVID-19 vaccination in the chronic kidney disease population

Matthew Oliver and Michelle Hladunewich, Sunnybrook Research Institute

Chronic kidney disease (CKD) patients are highly susceptible to infections, and COVID-19 infections in this group have lead to frequent hospitalizations and higher mortality rates. Among other things, this study is measuring the antibody response to COVID-19 vaccination in 4,000 CKD patients and determining how long the response lasts. Researchers will also review the vaccines’ safety in CKD patients.
Research summary Results

Vaccines in a Time of Dual Pandemic: COVID-19 Vaccine in People with HIV

Mario Ostrowski, University of Toronto

People with HIV infection (PWH) aged 55 and older who are on combined anti-retroviral therapy (cART) have greater immunity problems because of the effects of both HIV and aging on their immune systems. This study is investigating whether PWH 55 years and older receiving COVID-19 vaccines develop levels of immunity comparable to people without HIV infection.
Research summary Results

See our other funded research studies

See our other funded research studies